ScreenYu Gyn®
Cervical Cancer Screening
UnknownActive
Key Facts
About Epitype
Epitype GmbH is a molecular diagnostics company based in Jena, Germany, originally founded as oncgnostics GmbH in 2012 and rebranded in 2025. The company has developed and commercialized GynTect®, a DNA methylation-based test for cervical cancer, and is expanding its biomarker platform to other cancer types. Despite its innovative technology and product, the company's predecessor (oncgnostics GmbH) filed for insolvency in March 2025, indicating significant financial and operational challenges that the newly named entity must overcome.
View full company profileTherapeutic Areas
Other Cervical Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| CerviRaksha HPV Test | Karkinos Healthcare | Market |
| SureView Cervical Cytology System | Techcyte | Commercial |
| Vitro HPV Screening Assay | Appolon Bioteck | Approved/Commercial |
| Alinity m HR HPV Assay | Abbott | Commercial Launch |
| Aptima® HPV Assay Primary Screening | Hologic | FDA Approved |